Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,663 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | unknown | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT00530140 | Idiotypic Vaccination for Follicular Lymphoma Patients(FLIDVAX2006) | unknown | Phase 2 | 100 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 6, 2011 |
| clinicaltrials |
| NCT01114048 | Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)(KMM-97) | unknown | Phase 2 | 78 | Chonnam National University HospitalOTHER | 1 | Sep 22, 2011 | clinicaltrials |
| NCT01328236 | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia(Bortezomib) | unknown | Phase 2 | 20 | Clinical Service, ChinaINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT01221103 | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | unknown | Phase 1 / Phase 2 | 50 | Southern Europe New Drug OrganizationOTHER | 1 | Sep 13, 2011 | clinicaltrials |
| NCT01051115 | Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease(D'ACCORD) | unknown | Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 31, 2011 | clinicaltrials |
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 50 | University of LeipzigOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01322776 | Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2011 | clinicaltrials |
| NCT01277172 | TREatment of degeNerative and Neoplastic Diseases With Rituximab(TREND) | unknown | Phase 2 / Phase 3 | 54 | Probiomed S.A. de C.V.INDUSTRY | 1 | Jan 14, 2011 | clinicaltrials |
| NCT00923663 | Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Sep 28, 2010 | clinicaltrials |
| NCT00892827 | Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia | unknown | Phase 2 | 10 | Wolfson Medical CenterOTHER_GOV | 1 | Sep 14, 2010 | clinicaltrials |
| NCT00628238 | Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 2 | 80 | Chronic Lymphocytic Leukemia Research ConsortiumNETWORK | 1 | Sep 10, 2010 | clinicaltrials |
| NCT00508209 | Bortezomib and High-dose Melphalan at Myeloma Relapse | unknown | Phase 2 | 50 | Nordic Myeloma Study GroupOTHER | 3 | Jun 22, 2010 | clinicaltrials |
| NCT00868478 | The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 1 / Phase 2 | 15 | Kaplan Medical CenterOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT01066429 | DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Hospital Universitario Principe de AsturiasOTHER | 1 | Feb 12, 2010 | clinicaltrials |
| NCT00124813 | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | unknown | Phase 2 | 80 | University Hospital, BonnOTHER | 1 | Feb 2, 2010 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00946374 | Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma(HD-MCL2003) | unknown | Phase 2 | 20 | Heidelberg UniversityOTHER | 1 | Jul 27, 2009 | clinicaltrials |
| NCT00927797 | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)(PERLL) | unknown | Phase 2 | 185 | Heidelberg UniversityOTHER | 0 | Jun 25, 2009 | clinicaltrials |
| NCT00337519 | Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia | unknown | Phase 2 | 82 | Charite University, Berlin, GermanyOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00804947 | Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen | unknown | Phase 2 | 50 | Fundacion Para La Investigacion Hospital La FeOTHER | 1 | Dec 9, 2008 | clinicaltrials |
| NCT00800943 | Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy(CRC005) | unknown | Phase 2 | 31 | Chronic Lymphocytic Leukemia Research ConsortiumNETWORK | 1 | Dec 3, 2008 | clinicaltrials |
| NCT00722930 | Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma(GOTEL-FL1LC) | unknown | Phase 2 | 38 | Grupo Oncológico para el Tratamiento y el Estudio de los LinfomasOTHER | 1 | Jul 28, 2008 | clinicaltrials |
| NCT00415987 | Hematopoietic Stem Cell Transplantation in Myeloma | unknown | Phase 2 / Phase 3 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00702247 | Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi) | unknown | Phase 2 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00455416 | Dietary Intervention in Follicular Lymphoma(KLYMF) | unknown | Phase 2 | 45 | Oslo University HospitalOTHER | 1 | May 21, 2008 | clinicaltrials |
| NCT00349115 | TCD Followed by autoSCT for Newly Diagnosed MM Patients | unknown | Phase 2 | 43 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00109356 | Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 55 | NovaceaINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| NCT00327314 | Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma | unknown | Phase 2 | 100 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Dec 28, 2006 | clinicaltrials |
| NCT00048464 | T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | unknown | Phase 1 / Phase 2 | 35 | Xcyte TherapiesINDUSTRY | 1 | Nov 7, 2006 | clinicaltrials |
| NCT00261612 | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Oct 18, 2006 | clinicaltrials |
| NCT00382694 | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | unknown | Phase 2 | 80 | Nordic Myeloma Study GroupOTHER | 1 | Sep 29, 2006 | clinicaltrials |
| NCT00333008 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | unknown | Phase 2 | 27 | The Alvin and Lois Lapidus Cancer InstituteOTHER | 1 | Sep 26, 2006 | clinicaltrials |
| NCT00378755 | Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM | unknown | Phase 2 | 62 | Korean Multiple Myeloma Working PartyOTHER | 1 | Sep 22, 2006 | clinicaltrials |
| NCT00319865 | PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | unknown | Phase 2 | 47 | Korean Multiple Myeloma Working PartyOTHER | 1 | Apr 27, 2006 | clinicaltrials |
| NCT00311337 | VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) | unknown | Phase 2 | 61 | University of WuerzburgOTHER | 3 | Apr 5, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Oct 13, 2011source: clinicaltrials